Daniel Labow, MD
Surgical oncologist Dr. Daniel Labow is the system chair of surgical services at Nuvance Health and chair of surgery at Danbury Hospital in Danbury, Connecticut. He specializes in diagnosing and treating both primary and metastatic cancers of the gastric and esophageal systems, as well as primary and metastatic liver malignancies, colon and rectal cancer, pancreatic neoplasms, and malignant peritoneal mesothelioma. Dr. Labow is particularly skilled in performing cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal malignancies and has been responsible for establishing some of the country’s most robust HIPEC programs.[1]
Dr. Labow is dedicated to the delivery of high-quality surgery to patients.
Education and Career
Dr. Labow graduated from the Brown University Program in Liberal Medical Education, which combines undergraduate education and professional studies in medicine into a single, eight-year program. He completed his internship and residency in General Surgery at the University of Chicago Hospitals and Health System and then completed a fellowship in Surgery and Surgical Oncology at the Memorial Sloan-Kettering Cancer Center. He also earned a Master of Science degree in Healthcare Quality and Patient Safety from Northwestern University. He is a member of the American College of Surgeons.[1]
Dr. Labow joined Nuvance Health after over a decade of practice and leadership at the Icahn School of Medicine at Mount Sinai, where he had been the Vice Chair of Quality in the Department of Surgery and Executive Vice Chair of Quality for the Department of Surgery. While there, he led the HIPEC program to a position of national leadership.[1]
Research
Dr. Labow is passionate about cancer research, engaging in both studies of how to improve healthcare access, equity, and quality, and clinical trials meant to continue identifying ways to improve technology and treatments.[1]
His recent research includes:[2]
- Actual 5-Year Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis of Colorectal Origin. Sarfaty, E., Khajoueinejad, N., Yu, A. T., Hiotis, S., Golas, B. J., Sarpel, U., Labow, D. M. & Cohen, N. A., Mar 2024, In: Annals of Surgical Oncology. 31, 3, p. 1970-1979 10 p.
- ASO Visual Abstract: Actual 5-Year Survival After Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy For Patients With Peritoneal Carcinomatosis Of Colorectal Origin. Sarfaty, E., Khajoueinejad, N., Yu, A. T., Hiotis, S., Golas, B. J., Sarpel, U., Labow, D. M. & Cohen, N. A., 1 Mar 2024, In: Annals Of Surgical Oncology. 31, 3, P. 2021 1 P.
- ASO Visual Abstract: Postoperative Respiratory Failure Following Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy Is Associated With Volume Of Intraoperative Crystalloid Administration And Worse Survival. Pletcher, E., Cha, D. E., Gleeson, E., Shaltiel, T., Magge, D., Sarpel, U., Cohen, N., Labow, D. & Golas, B., 1 Jan 2023, In: Annals Of Surgical Oncology. 30, 1, P. 445-446 2 P.
- Association Of Systemic Chemotherapy Approaches With Outcomes In Appendiceal Peritoneal Metastases. Hanna, D. N., Macfie, R., Ghani, M. O., Hermina, A., Mina, A., Cha, D. E., Bailey, C. E., Cohen, N., Labow, D., Golas, B., Sarpel, U., Idrees, K. & Magge, D., Apr 2023, In: Journal Of Surgical Research. 284, P. 94-100 7 P.
- A Total Neoadjuvant Chemotherapy Approach Is Associated With Improved Recurrence-Free Survival In Patients With Colorectal Peritoneal Metastases Undergoing Cytoreductive Surgery And HIPEC. Hanna, D. N., Macfie, R., Ghani, M. O., Hermina, A., Mina, A., Cha, D. E., Bailey, C. E., Cohen, N., Labow, D., Golas, B., Sarpel, U., Magge, D. & Idrees, K., Mar 2023, In: Journal Of Surgical Oncology. 127, 3, P. 442-449 8 P.
